Tradestie Institutional Equity Comparison Engine

FGEN vs CRBP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

FGEN Overall Edge

FGEN Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to FibroGen, Inc (FGEN) driven by superior Valuation, Momentum & Technical while CRBP counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, FGEN trades at 61.4x Forward P/E with -499.1% operating margin (+774.8% YoY revenue) versus CRBP at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, FGEN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CRBP sits in BREAKDOWN (66th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner FGEN
FGEN 61.4x vs CRBP N/M Fwd P/E
Growth & Margin Winner CRBP
Op Margin -499.1% vs 0.0% ยท YoY +774.8% vs -100.0%
Momentum & Technical Winner FGEN
1Y -28.8% vs -69.5% ยท 52W Pos 44% vs 6%
Options & Structure Winner CRBP
UNCLASSIFIED (N/A IV) vs BREAKDOWN (66th %ile IV)
FGEN NASDAQ
FibroGen, Inc
Pharmaceutical Preparations
$9.71
+7.65% 1D
Market Cap $36.5M
1M Return +16.57%
1Y Return -28.84%
Forward P/E 61.4x
Unified AI Score
61.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 60.0
CRBP NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap $69.9M
1M Return -25.33%
1Y Return -69.51%
Forward P/E N/M
Unified AI Score
45.0 / 100 HOLD
Tech 43.0 Fund 54.0 Flow 69.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FGEN -28.84% CRBP -69.51% Spread: +31.0 pp (FGEN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
FGEN TTM Op. Margin: -499.1% CRBP TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FGEN vs CRBP. Trailing 12-month operating profitability (FGEN -499.1% vs CRBP 0.0%) and valuation multiples (FGEN 61.4x vs CRBP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FGEN (7) vs CRBP (3)
Institutional Metric FGEN CRBP Criterion Row Winner
Market Capitalization Scale $36.5M $69.9M Larger Scale CRBP
Trailing P/E Ratio Valuation 61.4x N/M Lower Multiple FGEN
Forward P/E Ratio Valuation 61.4x N/M Lower Multiple FGEN
Revenue Growth (YoY) Growth +774.8% -100.0% Higher Growth FGEN
Operating Margin (TTM) Profitability -499.1% 0.0% Higher Margin CRBP
Net Profit Margin Profitability 2598.9% 0.0% Higher Margin FGEN
Return on Equity (ROE) Capital Efficiency -1015.8% -131.5% Higher ROE CRBP
52-Week Range Position Momentum 44% ($0โ€“$22) 6% ($3โ€“$13) Stronger Trend FGEN
Beta / 30D Volatility Risk Regime -20.79ฮฒ ยท 102% Vol 1.93ฮฒ ยท 121% Vol Lower Realized Risk FGEN
Unified Institutional Score Composite Signal 61.2 / 100 (BUY) 45.0 / 100 (HOLD) Higher Composite FGEN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FGEN vs CRBP Buy Guide
FGEN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live FGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRBP BREAKDOWN
58d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 66th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live CRBP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FGEN nor CRBP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.